TY - JOUR T1 - RPA-Based Method For The Detection Of SARS-COV2 JF - medRxiv DO - 10.1101/2020.09.17.20196402 SP - 2020.09.17.20196402 AU - Angus A. Nassir AU - Mazarati Jean Baptiste AU - Ivan Mwikarago AU - Majidi R. Habimana AU - Janvier Ndinkabandi AU - Anthere Murangwa AU - Thierry Nyatanyi AU - Claude Mambo Muvunyi AU - Sabin Nsanzimana AU - Mutesa Leon AU - Clarisse Musanabaganwa Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20196402.abstract N2 - Background Coronavirus disease 2019 (COVID-19) is a highly infectious disease with significant mortality, morbidity, and far-reaching economic and social disruptions. Testing is key in the fight against COVID-19 disease. The gold standard for COVID-19 testing is the reverse transcription polymerase chain reaction (RT-PCR) test. RT-PCR requires highly specialized, expensive, and advanced bulky equipment that is difficult to use in the field or in a point of care setting. There is need for a simpler, inexpensive, convenient, portable and accurate test. Our aims were to: (i) design primer-probe pairs for use in isothermal amplification of the S1, ORF3 and ORF8 regions of the SARS-CoV2 virus; (ii) optimize the recombinase polymerase amplification (RPA) assay for the isothermal amplification of the named SARS-COV2 regions; (iii) detect amplification products on a lateral flow device. and (ii) perform a pilot field validation of RPA on RNA extracted from nasopharyngeal swabs.Results Assay validation was done at the National Reference Lab (NRL) at the Rwanda Biomedical Center (RBC) in Rwanda. Results were compared to an established, WHO-approved rRT-PCR laboratory protocol. The assay provides a faster and cheaper alternative to rRT-PCR with 100% sensitivity, 93% specificity, and positive and negative predictive agreements of 100% and 93% respectively.Conclusion To the best of our knowledge, this is the first in-field and comparative laboratory validation of RPA for COVID-19 disease in low resource settings. Further standardization will be required for deployment of the RPA assay in field settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no financial support for the research, authorship, and/or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Expedited ethical review approval of the study was obtained from the Rwanda National Ethics Committee (RNEC- IRB00001497). The Laboratory validation relied on retrospective data and biological samples which were put together as part of routine care of COVID-19 patients. Confidentiality has been respected through the use of codes instead of names. IRB review and oversight is not required because the activities involve secondary de-identified biospecimans.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that the data supporting the findings of this study are available within the article and its supplementary information files ER -